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Introduction
Multiple sclerosis (MS) is an autoimmune-mediated 
disease predominantly affecting women and with a 
median age of onset of approximately 30 years. Many 
of the affected patients are women in their childbear-
ing years. Therefore, the safety of MS-directed dis-
ease-modifying therapies during pregnancy and 
lactation is a topic of increasing importance. The 
monoclonal antibody natalizumab (NAT) is approved 
for the treatment of highly active relapsing-remitting 
multiple sclerosis (RRMS). By blocking very-late-
antigen (VLA)-4 on the surface of lymphocytes, it 
prevents transmigration of these cells via the blood–
brain barrier (BBB) and reduces inflammation in the 
central nervous system.1,2 If a woman with highly 
active RRMS plans to become pregnant, risks of 
exposure with NAT during pregnancy have to be bal-
anced with risks of returning disease activity after 
NAT cessation. NAT is classified as a pregnancy cat-
egory C drug, which reflects the lack of adequate and 
well-controlled studies in humans. In animal studies 
on guinea pigs and cynomolgus monkeys, no fetotox-
icity or teratogenic effects have been attributed to 
NAT; however, varying results for increased abortion 
rates have been reported.3–5 Studies in guinea pigs and 
primates have shown that NAT can pass through the 
placental barrier in late-stage pregnancy and can 
cause hematological effects on fetal guinea pigs and 
primates.3,5 Other studies have not identified any 
impact on the fetus.4 Until now, human studies and 
case reports have documented mostly positive out-
comes of pregnancy;6–10 however, results are limited 
by small sample sizes. Schneider et al.11 reported a 
significant reduction in CXCL12-induced chemotaxis 
rate of T lymphocytes in two cases. In one case series, 
hematological alterations including thrombocytope-
nia, anemia, and leukocytosis were found in 12 
women during 13 pregnancies and 10 newborns.12 
Currently, data available about NAT levels in breast 
milk, umbilical cord blood, and blood of the newborn 
are scarce. Haghikia et al.12 detected NAT in serum of 
five mother–infant pairs, and Baker et al.13 reported 
one case with free NAT in breast milk. Here, we pre-
sent NAT serum levels as well as cell-bound lympho-
cyte NAT saturation in 11 mother–infant pairs. 
Additionally, we have investigated the time course of 
Natalizumab during pregnancy and lactation
Undine Proschmann, Katja Thomas, Sandra Thiel, Kerstin Hellwig and Tjalf Ziemssen
Abstract
Background: Managing medication during pregnancy and lactation in multiple sclerosis (MS) patients 
needs to balance potential risks to the newborn with the substantial risks of ongoing disease activity.
Objective: To evaluate the potential transfer of natalizumab (NAT) into breast milk and into the serum of 
newborn babies in women who continued NAT treatment during pregnancy and lactation.
Methods: Serum samples of 11 mother–infant pairs and mother milk samples of a further 4 women were 
analyzed for free NAT using a HL60 cell-based fluorescence-activated cell sorting (FACS) assay. Two 
mother–baby pairs were analyzed for cell-bound NAT, very-late-antigen (VLA)-4 expression, and satura-
tion with NAT on immune cells by FACS analysis.
Results: In the majority of the mother–infant serum pairs (6/11) and in all breast milk samples, free NAT 
was detectable. Cell-bound NAT was measurable in both mother–baby pairs with significant higher lev-
els in babies. VLA-4 expression seems to be higher in newborns. Saturation with NAT was comparable 
between newborns and mothers.
Conclusion: NAT can pass placental barrier before delivery and into breast milk. Measurable NAT on 
neonatal lymphocytes may have functional impact. Further investigations are needed to clarify safety and 
risk of NAT exposure during pregnancy and lactation.
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NAT levels in breast milk of four mothers up to 
5.5 months after delivery.
Methods
Patients
Pregnancy cohort. Serum from a total of 11 
mother–infant pairs was analyzed for free NAT. 
Serum samples were collected directly after deliv-
ery. The majority of blood samples from the new-
born were taken from the umbilical cord. Two of the 
11 patients were treated with standard dose of NAT 
(300 mg monthly) during whole pregnancy, and one 
patient had received NAT during first trimester and 
then decided to discontinue treatment, restarting the 
drug at a later date during the pregnancy due to 
relapse. In the other eight patients, NAT therapy 
was withdrawn between 6 and 2 months before 
delivery. Measurement of cell-bound NAT, VLA-4 
expression, and saturation with NAT was performed 
for 2 of the 11 pairs (Table 1). Three women pre-
sented with MS relapses during pregnancy; one 
woman had two relapses. In two of these three 
women, NAT treatment was withdrawn 3 and 
6 months before the relapse and one woman was 
retreated with NAT during pregnancy. The patient 
with two relapses had received NAT treatment dur-
ing whole pregnancy. All of three patients received 
intravenous corticosteroids for relapse treatment. 
Additionally, blood samples were collected from 9 
newborns of the 11 mother–infant pairs for evalua-
tion of hematological alterations.
Breastfeeding cohort. For the analysis of free NAT 
in the breast milk, breast milk samples from four 
mothers were collected prospectively (Table 2). 
None of these women suffered from a relapse dur-
ing pregnancy or postpartum period. All patients 
from cohort 2 received monthly NAT infusions with 
the standard dose of 300 mg during pregnancy and 
breastfeeding period.
The study was performed according the Declaration 
of Helsinki, and the study protocol was approved by 
the Ethics Committee, Faculty of Medicine, Dresden 
University of Technology and Department of 
Neurology, St. Josef-Hospital, Ruhr University 
Bochum. All patients provided written informed 
consent.
Analyses
For the analysis of free NAT concentration, serum 
samples (undiluted and diluted 1:10 to 1:750) were 
added to HL60 cells in order to perform a HL60-based 
fluorescence-activated cell sorting (FACS) assay as 
previously described.14 To measure cell-bound NAT, 
VLA-4 expression, and NAT saturation, peripheral 
blood mononuclear cells were isolated from heparin-
ized blood samples using Biocoll separating solution 
(Biochrom Ag) and Ficoll Paque (Amersham 
Biosciences) in LeucoSep tubes (Greiner Bio One). 
Cells were then stained with fluorescence-labeled 
anti-CD3 (BD Biosciences), anti-CD19 (BD 
Biosciences), anti-immunoglobulin (Ig)-G4 (Southern 
Biotech), and anti-CD49d (BD Biosciences) 
Table 1. Clinical characteristics of the mothers.
Patient Age 
(years)
Disease 
duration 
(years)
NAT 
infusion 
number
Relapses 
during 
pregnancy (n)
Relapse 
treatment
Prior treatment to NAT
M1 29 5 27 1 Steroids, 5g Interferon beta-1b (Betaferon®), 
glatimeracetat
M2 39 5 37 0 Interferon beta-1a (Avonex®)
M3 31 9 n.a. 0 Glatimeracetat, interferon beta-1a (Rebif®)
M4 31 0.5 11 0 No prior treatment
M5 33 6 13 2 Steroids, 5g Interferon beta-1a (Avonex, Rebif)
M6 32 10 64 0 Interferon beta-1a (Rebif)
M7 36 15 16 1 Steroids, 3g Interferon beta-1a (Avonex), interferon 
beta-1b (Betaferon)
M8 32 7 64 0 Glatimeracetat, interferon beta-1a (Rebif)
M9 35 2 31 0 No prior treatment
M10 29 1 10 0 Interferon beta-1a (Rebif)
M11 29 0.5 10 0 No prior treatment
NAT: natalizumab; n.a.: not available.
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antibodies. Isotype and negative cells were used as 
controls. Laboratory findings reported in Table 3 were 
obtained using routine blood analyses in certified 
diagnostic laboratories.
Maternal breast milk samples were collected up to 
145 days after delivery and frozen at −20°C directly 
after collection. For analysis of free NAT, samples 
were first thawed and then centrifuged for separation 
of lipids. Afterwards, 10 µg of undiluted and diluted 
(1:10 and 1:100) breast milk samples were added to 
HL60 cells, and the same HL60-based FACS assay 
described above was applied.
Statistical analysis
Data are expressed as mean values with standard 
deviation. The unpaired t-test was used for group 
comparisons. p < 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using 
Graph Pad Prism 5.
Results
Free NAT is present in serum of treated mothers 
and their newborn
Free NAT was detectable in the majority of the 
mother–infant serum pairs (6/11) (Figure 1). NAT 
was only detectable when the last infusion was 
given less than 75 days before delivery. In general, 
the mother–infant serum pairs with the most recent 
exposure to NAT infusion had the highest NAT lev-
els. Levels of free NAT concentration ranged 
between 69 and 19,700 ng/mL in newborns, and 
between 122 and 19,200 µg/mL in mothers, indicat-
ing a great inter-individual variability. In four of 
the mother–infant pairs with detectable NAT, the 
concentration was higher in the mothers than in the 
newborns, whereas in two other mother–infant 
pairs, NAT levels were higher in the infants than in 
the mothers (Figure 1).
Table 2. Patient characteristics of the breastfeeding mothers.
Patient Age 
(years)
Disease 
duration 
since RRMS 
diagnosis 
(years)
Total number 
of NAT 
infusion (n)
Relapses 
during 
pregnancy 
(n)
Prior treatment to 
NAT
EDSS 
before 
delivery
NAT 
treatment 
during 
pregnancy
M12 29 5 36 0 Interfon beta 1-a 1.5 Yes
M13 25 1  9 0 Interferon beta 1-a 2.0 Yes
M14 34 4 55 0 No prior treatment 1.5 Yes
M15 36 3 45 0 Fingolimod 2.5 Yes
RRMS: relapsing-remitting multiple sclerosis; NAT: natalizumab; EDSS: Expanded Disability Status Scale.
Table 3. Hematological characteristics of the newborn.
Newborn Anemia Thrombocytopenia
N1 no no
N2 n.a. n.a.
N3 no yes
N4 yes yes
N5 yes yes
N6 yes no
N7 no no
N8 n.a. n.a.
N9 yes no
N10 yes no
N11 no no
n. a.: not available.
Figure 1. Free NAT concentration in blood. Free 
natalizumab (NAT) serum concentration levels () in 
mothers and their newborns were determined using a 
HL60 cell-based assay. In the majority of mother–infant 
pairs (6/11), free NAT was detectable in a range from 69 to 
19,700 ng/mL.
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Cell-bound NAT, VLA-4 expression, and 
saturation with NAT on T- and B-cells
Cell-bound NAT, VLA-4 expression, and saturation 
with NAT were measured on CD3+ T-cells and 
CD19+ B-cells of four mother–baby pairs. A mean 
fluorescence intensity (MFI) of NAT on the cell sur-
face of 1634 ± 116.1 was observed on CD3+ T-cells of 
the newborns compared to a significant lower MFI of 
925.3 ± 63.25 in the respective mothers (p = 0.012) 
(Figure 2(a)). On CD 19+ B-cells, MFI was 
1366 ± 70.37 in the newborns and 910.8 ± 100.7 in the 
mothers (difference statistically significant p = 0.015) 
(Figure 2(a)). There was no significant correlation 
between free and cell-bound NAT. For VLA-4 expres-
sion on CD 3+ T-cells, an MFI of 2014 ± 423.1 was 
measured in the newborns and 1106 ± 188.1 was 
recorded in the respective mothers (Figure 2(b)). On 
CD 19+ B-cells, MFI was 1378 ± 118.2 in the babies 
and 1066 ± 128.0 in the mothers. VLA-4 expression 
was lower in the mothers compared to the newborns, 
but did not reach statistical significance (Figure 2(b)). 
There was no significant difference in NAT saturation 
on CD3+ T-cells and CD19+ B-cells between mothers 
and their newborns (Figure 2(c)).
Figure 2. Cell-bound NAT, VLA-4 expression, and NAT saturation in blood. Mean fluorescence intensity (MFI) values 
for (a) cell-bound NAT, (b) very-late-antigen (VLA)-4 expression, and (c) saturation with NAT on CD3+ T-cells and 
CD19+ B-cells were observed in the two newborns () and their mothers (). Negative controls () were included. 
*p < 0.05; **p < 0.01.
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Hematological abnormalities in the newborn
Hematological abnormalities were found in six new-
borns including anemia (n = 5) and thrombocytopenia 
(n = 3). In two newborns, both anemia and thrombocy-
topenia were detected (Table 3). The mothers of the 
newborns with hematological abnormalities received 
their last NAT infusion between 3 and 1 month before 
delivery. Occurrence of hematological alterations 
seems to be associated to NAT treatment during the 
third trimester. We could not observe a clear associa-
tion between the amount of free NAT in the newborn 
and detectable hematological alterations.
NAT is detectable in breast milk of NAT-treated 
breastfeeding mothers
NAT was detectable in the majority of the breast milk 
samples of all four mothers with a concentration 
range between 2 and 412 ng/mL, presenting again 
with a large inter-individual variability (Figure 3). 
The concentration level of free NAT in breast milk 
was significantly correlated (r = 0.2271) to the time 
period since the last NAT infusion (Figure 4).
Discussion
Here, we present a systematic evaluation of peripheral 
blood samples and breast milk of NAT-treated moth-
ers and their newborns. Transport of maternal anti-
bodies via placental barrier starts in the second 
trimester with rates increasing as the pregnancy pro-
gresses.15 Unsurprisingly, monoclonal antibodies are 
also transported via placental barrier, and this has 
been reported for the therapeutics adalimumab and 
infliximab.16 The placental transport of the monoclo-
nal antibody NAT was first described by Haghikia 
et al.12 In our study, we could also detect free NAT in 
serum of newborns in all mother–infant pairs, provid-
ing the last NAT infusion was not longer than 
2.5 months ago, which is in line with our previous 
pharmacokinetic data.14 NAT levels demonstrate a 
great deal of inter-individual variability. Here, we 
could demonstrate for the first time that the cell-
bound NAT concentration is higher on infant CD3+ 
T-cells and CD19+ B-cells compared to the cells of 
the mother. Additionally, we observed that the expo-
sure to NAT during the third trimester of pregnancy is 
associated with hematological abnormalities includ-
ing anemia and thrombocytopenia in the newborns. 
Despite the small sample size of our analysis, these 
data indicate that NAT is present in newborns and 
might have the potential to act as a functional blocker 
of VLA-4. In order to evaluate the functional impact 
of placental NAT transport, further investigations of 
cell-bound NAT, VLA-4 expression, NAT saturation, 
and the change in these parameters over time are 
needed. We also demonstrate that NAT is detectable 
in the breast milk including a significant association 
with the time since the last NAT infusion. According 
to the conventional model of drug passage into breast 
milk, large molecules such as maternal immunoglob-
ulins can pass into colostrum because of the wide 
spaces between mammary epithelial cells. The pores 
begin to close at onset of lactogenesis and are fully 
closed by days 10–14 postpartum, which prohibits the 
direct passage of molecules with a molecular weight 
higher than 800 Da. According to this model, biosyn-
thetic monoclonal antibodies should not pass into 
breast milk due to their molecular weight of about 
140,000 Da. Nevertheless, for some monoclonal anti-
bodies, such as etanercept, infliximab, and ipili-
mumab, passage into breast milk has already been 
demonstrated.17–19 In accordance with Baker et al.,13 
we were also able to show that NAT is transferred into 
breast milk, and that levels of free NAT appear to 
increase over time. So far, a steady state for the breast 
milk is not determined. The intestinal transfer of 
maternal IgG from colostrum to the neonate is sparse 
in humans.20 Gut closure occurs before birth and only 
a little amount of immunoglobulins is absorbed via 
intestine after birth.21,22 Post-closure uptake of IgG 
can occur via the neonatal Fc receptor (FcRn). FcRn, 
also known as Brambell receptor, is a major histo-
compatibility complex (MHC) class I–like molecule. 
Lu et al.23 mentioned that the FcRn protects immuno-
globulin G (IgG) from catabolism, and that FcRn is 
also responsible for IgG absorption in the small intes-
tine of neonatal rats. By immunohistochemical analy-
ses, Israel et al.24 demonstrated that FcRn is also 
expressed in human epithelial cells. Shah et al.25 
observed that the FcRn is expressed in the stomach, 
small intestine, and colon of human fetal. Additionally, 
Israel et al.26 demonstrated that human fetal FcRn 
could bind IgG with similar characteristics to that 
seen in neonatal rats. Therefore, it might be possible 
that small amounts of monoclonal antibodies are 
transported from the gut to the plasma of the new-
borns. In order to recommend women on monoclonal 
antibodies concerning drug safety during lactation, 
more data are needed regarding NAT levels in breast 
milk, and ideally in infant plasma as well.
Due to the fact that potential hematology complica-
tions like thrombocytopenia and anemia can occur, 
we recommend in accordance with Haghikia et al.12 
that patients receiving NAT for the whole duration of 
pregnancy should give birth in a hospital with signifi-
cant pediatric experience, and that the newborns 
should be screened for hematological adverse events 
such as those listed above.
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Although our observation is limited by the small sam-
ple size and by the different breast milk sample col-
lection procedures, our data clearly show that NAT 
can pass the placental barrier, is detectable in new-
borns after delivery, and is transferred into breast 
milk. Our data emphasize the need to carefully 
outweigh risks and benefits in the clinical decision to 
continue NAT treatment during pregnancy and lacta-
tion. If therapy is continued, babies should be care-
fully screened for hematological abnormalities. 
Further investigations, using standardized sample col-
lection protocols, are needed to fully understand the 
Figure 3. Free NAT in breast milk. Free NAT concentration in breast milk ( ) was analyzed in four mothers (a–d) using 
a HL60 cell-based assay. Timepoints of NAT infusion ( ) and delivery (  ) are shown. In the majority of breast milk 
samples, free NAT was detectable with a range of 2–412 ng/mL.
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mode and impact of NAT-transfer from mother to 
newborn via breast milk.
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